AAAAAA

   
Results: 1-25 | 26-43
Results: 1-25/43
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer
Authors: Lippman, SM Lee, JJ Karp, DD Vokes, EE Benner, SE Goodman, GE Khuri, FR Marks, R Winn, RJ Fry, W Graziano, SL Gandara, DR Okawara, G Woodhouse, CL Williams, B Perez, C Kim, HW Lotan, R Roth, JA Hong, WK
Citation: Sm. Lippman et al., Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer, J NAT CANC, 93(8), 2001, pp. 605-618
Esophageal cancer therapy: A decade of inertia
Authors: Cohen, EEW Vokes, EE
Citation: Eew. Cohen et Ee. Vokes, Esophageal cancer therapy: A decade of inertia, CANCER J, 7(5), 2001, pp. 369-371
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer
Authors: Mantz, CA Vokes, EE Stenson, K Kies, MS Mittal, B Witt, ME List, MA Weichselbaum, RR Haraf, DJ
Citation: Ca. Mantz et al., Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer, CANCER J, 7(2), 2001, pp. 140-148
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial
Authors: Khuri, FR Kim, ES Lee, JJ Winn, RJ Benner, SE Lippman, SM Fu, KK Cooper, JS Vokes, EE Chamberlain, RM Williams, B Pajak, TF Goepfert, H Hong, WK
Citation: Fr. Khuri et al., The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial, CANC EPID B, 10(8), 2001, pp. 823-829
Sequential induction chemotherapy and concomitant chemoradiotherapy in themanagement of locoregionally advanced laryngeal cancer
Authors: Mantz, CA Vokes, EE Kies, MS Mittal, B Witt, ME List, MA Weichselbaum, RR Haraf, DJ
Citation: Ca. Mantz et al., Sequential induction chemotherapy and concomitant chemoradiotherapy in themanagement of locoregionally advanced laryngeal cancer, ANN ONCOL, 12(3), 2001, pp. 343-347
Gene therapy for head and neck cancers - The Lamont et al article reviewed
Authors: Cohen, EEW Vokes, EE
Citation: Eew. Cohen et Ee. Vokes, Gene therapy for head and neck cancers - The Lamont et al article reviewed, ONCOLOGY-NY, 15(3), 2001, pp. 311-312
Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer
Authors: Vokes, EE
Citation: Ee. Vokes, Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer, LUNG CANC, 33, 2001, pp. S85-S89
A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest
Authors: George, CM Haraf, DJ Mauer, AM Krauss, SA Hoffman, PC Rudin, CM Szeto, L Vokes, EE
Citation: Cm. George et al., A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest, INV NEW DR, 19(4), 2001, pp. 303-310
A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer
Authors: Vokes, EE Gordon, GS Rudin, CM Mauer, AM Watson, S Krauss, S Arrieta, R Golomb, HM Hoffman, PC
Citation: Ee. Vokes et al., A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer, INV NEW DR, 19(4), 2001, pp. 329-333
Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer
Authors: Brockstein, B Samuels, B Humerickhouse, R Arietta, R Fishkin, P Wade, J Sosman, J Vokes, EE
Citation: B. Brockstein et al., Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer, INV NEW DR, 19(3), 2001, pp. 249-254
Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer
Authors: Hainsworth, JD Vokes, EE
Citation: Jd. Hainsworth et Ee. Vokes, Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer, SEMIN ONCOL, 28(1), 2001, pp. 22-27
Elimination pathways of [C-14]losoxantrone in four cancer patients
Authors: Joshi, AS Pieniaszek, HJ Vokes, EE Vogelzang, NJ Davidson, AF Richards, LE Chai, MF Finizio, M Ratain, MJ
Citation: As. Joshi et al., Elimination pathways of [C-14]losoxantrone in four cancer patients, DRUG META D, 29(2), 2001, pp. 96-99
Distribution and functional consequences of nucleotide polymorphisms in the 3 '-untranslated region of the human Sep15 gene
Authors: Hu, YJ Korotkov, KV Mehta, R Hatfield, DL Rotimi, CN Luke, A Prewitt, TE Cooper, RS Stock, W Vokes, EE Dolan, ME Gladyshev, VN Diamond, AM
Citation: Yj. Hu et al., Distribution and functional consequences of nucleotide polymorphisms in the 3 '-untranslated region of the human Sep15 gene, CANCER RES, 61(5), 2001, pp. 2307-2310
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea
Authors: Innocenti, F Stadler, WM Iyer, L Ramirez, J Vokes, EE Ratain, MJ
Citation: F. Innocenti et al., Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea, CLIN CANC R, 6(9), 2000, pp. 3400-3405
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer
Authors: Brockstein, B Haraf, DJ Stenson, K Sulzen, L Witt, ME Weichselbaum, RW Vokes, EE
Citation: B. Brockstein et al., A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer, ANN ONCOL, 11(6), 2000, pp. 721-728
The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy - The feasibility of selective neck dissection
Authors: Stenson, KM Haraf, DJ Pelzer, H Recant, W Kies, MS Weichselbaum, RR Vokes, EE
Citation: Km. Stenson et al., The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy - The feasibility of selective neck dissection, ARCH OTOLAR, 126(8), 2000, pp. 950-956
Swallowing function in patients with head and neck cancer prior to treatment
Authors: Stenson, KM MacCracken, E List, M Haraf, DJ Brockstein, B Weichselbaum, R Vokes, EE
Citation: Km. Stenson et al., Swallowing function in patients with head and neck cancer prior to treatment, ARCH OTOLAR, 126(3), 2000, pp. 371-377
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer
Authors: Kies, MS Haraf, DJ Rosen, F Stenson, K List, M Brockstein, B Chung, T Mittal, BB Pelzer, H Portugal, L Rademaker, A Weichselbaum, R Vokes, EE
Citation: Ms. Kies et al., Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer, J CL ONCOL, 19(7), 2000, pp. 1961-1969
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer
Authors: Vokes, EE Kies, MS Haraf, DJ Stenson, K List, M Humerickhouse, R Dolan, ME Pelzer, H Sulzen, L Witt, ME Hsieh, YC Mittal, BB Weichselbaum, RR
Citation: Ee. Vokes et al., Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer, J CL ONCOL, 18(8), 2000, pp. 1652-1661
How do head and neck cancer patients prioritize treatment outcomes before initiating treatment?
Authors: List, MA Stracks, J Colangelo, L Butler, P Ganzenko, N Lundy, D Sullivan, P Haraf, D Kies, M Goodwin, W Vokes, EE
Citation: Ma. List et al., How do head and neck cancer patients prioritize treatment outcomes before initiating treatment?, J CL ONCOL, 18(4), 2000, pp. 877-884
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago phase II consortium study
Authors: Stadler, WM Vogelzang, NJ Amato, R Sosman, J Taber, D Liebowitz, D Vokes, EE
Citation: Wm. Stadler et al., Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago phase II consortium study, J CL ONCOL, 18(2), 2000, pp. 371-375
Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532
Authors: Perry, MC Ihde, DC Herndon, JE Grossbard, ML Grethein, SJ Atkins, JN Vokes, EE Green, MR
Citation: Mc. Perry et al., Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532, LUNG CANC, 28(1), 2000, pp. 63-68
CI-980 in advanced melanoma and hormone refractory prostate cancer
Authors: Ryan, CW Shulman, KL Richards, JM Kugler, JW Sosman, JA Ansari, RH Vokes, EE Vogelzang, NJ
Citation: Cw. Ryan et al., CI-980 in advanced melanoma and hormone refractory prostate cancer, INV NEW DR, 18(2), 2000, pp. 187-191
Lung cancer
Authors: Hoffman, PC Mauer, AM Vokes, EE
Citation: Pc. Hoffman et al., Lung cancer, LANCET, 355(9202), 2000, pp. 479-485
The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer
Authors: Vokes, EE Haraf, DJ Kies, MS
Citation: Ee. Vokes et al., The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer, SEMIN ONCOL, 27(4), 2000, pp. 34-38
Risultati: 1-25 | 26-43